Pomerantz LLP Investigates Claims of Securities Fraud by Sage Therapeutics


Pomerantz LLP, a renowned law firm specializing in corporate and securities class litigation, is currently conducting an investigation into allegations of securities fraud by Sage Therapeutics, Inc. The company’s investors are advised to reach out to Danielle Peyton, an attorney at Pomerantz LLP, for more information.

The investigation centers around accusations that Sage, along with certain officers and directors, may have engaged in securities fraud or other illegal business practices. The firm aims to uncover the truth and seek justice for the potential victims of these alleged wrongdoings.

Recently, on April 17, 2024, Sage issued a press release regarding the results of a Phase 2 study for their investigational oral medicine, dalzanemdor (SAGE-718), which targeted people with mild cognitive impairment in Parkinson’s Disease. Unfortunately, the study failed to meet its primary endpoint of demonstrating a statistically significant difference from baseline among participants treated with once-daily dalzanemdor versus the placebo. This announcement caused Sage’s stock price to plummet by $3.06 per share, equivalent to a 19.58% decrease, closing at $12.57 per share on the same day.

Pomerantz LLP, with its offices in major cities like New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is recognized as one of the top firms specializing in corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, a widely respected figure in the class action bar, the firm has been instrumental in pioneering securities class actions. Upholding the legacy of its founder, Pomerantz continues to fight for the rights of securities fraud victims, breaches of fiduciary duty, and corporate misconduct, having successfully recovered billions of dollars for its clients.

If you are an investor in Sage Therapeutics and believe you may have been affected by the alleged fraud, please contact Danielle Peyton at Pomerantz LLP by email at [email protected] or call 646-581-9980, ext. 7980. Remember, past results may not guarantee similar outcomes, and this communication is considered attorney advertising.

Source: Pomerantz LLP

In addition to the information provided in the article, it is important to consider some of the current market trends related to Sage Therapeutics and the pharmaceutical industry as a whole.

1. Growing Demand for Innovative Treatments: The pharmaceutical industry is witnessing a growing demand for innovative treatments targeting various medical conditions. This demand has created significant opportunities for companies like Sage Therapeutics to develop new drugs and therapies.

2. Increased Focus on Mental Health: There is a growing awareness and focus on mental health conditions, including cognitive impairments. Companies that can provide effective treatments in this area are likely to attract attention from investors and patients alike.

As for forecasts, it is challenging to provide specific forecasts for Sage Therapeutics as it depends on various factors such as the success of their ongoing clinical trials and the overall market conditions. However, it is worth noting that the failure of the recent Phase 2 study for dalzanemdor could impact the company’s future plans and investor sentiment.

One of the key challenges facing Sage Therapeutics is the highly regulated nature of the pharmaceutical industry. Developing and gaining regulatory approval for new drugs is a lengthy and costly process. The failure of a clinical trial, like in the case of dalzanemdor, can result in significant setbacks for the company.

Furthermore, controversies associated with allegations of securities fraud can erode investor confidence and lead to legal implications for Sage Therapeutics. The ongoing investigation by Pomerantz LLP adds additional uncertainty to the situation.

Despite these challenges and controversies, Sage Therapeutics still has the potential to recover and regain investor trust. Their pipeline of drugs and therapies, including zuranolone for major depressive disorder, continue to show promise and could contribute to future success if the clinical trials yield positive results.

For additional information on securities fraud and related topics, you may visit the Securities and Exchange Commission (SEC) website. They provide resources and insights into various aspects of securities fraud and regulations: SEC Website.

It is important to note that investing in companies like Sage Therapeutics involves risks, and individuals should carefully consider their investment decisions based on their own financial circumstances and goals.